- Pharmaxis attracts A$0.53 price target in coverage initiation from MST Access
- Pharmaxis’ treatment to prevent wound and burns scars clears phase1 trial
- Pharmaxis welcomes green light to progress to Phase 2 bone marrow cancer trial
Quick facts: Pharmaxis Ltd
Price: 0.11 AUD
Market Cap: $49.98 m
About the company
Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis.
The company has a highly productive drug discovery engine, drug candidates in clinical trials and two respiratory products approved in global markets generating ongoing revenue.
Pharmaxis’ lead drug candidate (PXS-5505) is for the treatment of the bone marrow cancer myelofibrosis, which affects 1 in 500,000 people.
Another Pharmaxis drug discovery, PXS‐6302 has entered a world-first clinical trial aiming to stop scars that are formed after surgery or trauma, particularly following burn injuries.
Pharmaxis has developed two products from its proprietary spray drying technology that …